Clinical Trials Browser

Neoplasm, Residual × Pentostatin × 1 year × Clear all

NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Phase 2 Active not recruiting

69 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual